Histapharm

Histapharm Inc. is a Canadian biopharmaceutical research company that has developed a patented bi-enzymatic platform designed to regulate histamine levels by degrading excess histamine directly in the gut. The company’s therapeutic approach uses a combination of vegetal diamine oxidase (vDAO) and catalase, which is formulated for intestinal delivery. This mechanism aims to address the root cause of histamine-related issues by catabolizing histamine molecules, offering an alternative to traditional antihistamine technologies that primarily function by blocking histamine receptors.

This platform is intended to support the development of novel therapeutics for conditions linked to histamine excess or dysfunctions associated with DAO inhibition, such as inflammation, inflammatory bowel diseases, allergies, and various enteric diseases. By targeting histamine degradation rather than receptor suppression, Histapharm seeks to provide solutions for patients suffering from chronic histamine-related symptoms. The company has engaged in strategic partnerships, such as those with Devonian Health Group, to facilitate the manufacturing and development of its proprietary botanical drug candidates for pharmaceutical and nutraceutical applications.